Skip to main content
Addgene

Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.

Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL
Nat Biotechnol. 2014 Jun 22. doi: 10.1038/nbt.2951. (Link opens in a new window) PubMed (Link opens in a new window) Article

Plasmids from Article

ID Plasmid Purpose
57818pL-CRISPR.EFS.GFPLentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA. Coexpresses eGFP via P2A cleavage site. EFS Promoter driven
57819pL-CRISPR.EFS.tRFPLentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA. Coexpresses tagRFP via P2A cleavage site. EFS Promoter driven
57821pLKO5d.EFS.SpCas9.P2A.BSDLentiviral Vector for SpCas9 Expression without sgRNA, Blasticidin resistance, EFS Promoter driven
57822pLKO5.sgRNA.EFS.GFP3rd generation lentiviral Vector for Sp sgRNA delivery without SpCas9, GFP, EFS Promoter driven
57823pLKO5.sgRNA.EFS.tRFP3rd generation Lentiviral Vector for Sp sgRNA delivery without SpCas9, tagRFP, EFS Promoter driven
57824pLKO5.sgRNA.EFS.tRFP657Lentiviral Vector for Sp sgRNA delivery without SpCas9, tagRFP657, EFS Promoter driven
57825pLKO5.sgRNA.EFS.PACLentiviral Vector for Sp sgRNA delivery without SpCas9, Puromycin resistance, EFS Promoter driven
57826pL-CRISPR.SFFV.tRFPLentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA. Coexpresses tagRFP via P2A cleavage site. SFFV Promoter driven
57827pL-CRISPR.SFFV.GFPLentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA. Coexpresses eGFP via P2A cleavage site. SFFV Promoter driven
57828pL-CRISPR.EFS.PACLentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA, Puromycin resistance, EFS Promoter driven
57829pL-CRISPR.SFFV.PACLentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA, Puromycin resistance, SFFV Promoter driven
58329pLKO5d.EFS.SpCas9.P2A.PACLentiviral Vector for SpCas9 Expression without sgRNA, Puromycin resistance, EFS Promoter driven
61395pL-SFFV.Reporter.RFP657.PACLentiviral vector for RFP657 NHEJ reporter system expression. Allows insertion of target sites between the SFFV promoter and RFP657 for detection of fluorescence knockdown. Puromycin resistance.

Antibodies from Article